Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov;74(2):226-227.
doi: 10.1007/s12020-021-02879-8. Epub 2021 Sep 17.

Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves' disease

Chutintorn Sriphrapradang  1
Affiliations
Comment

Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves' disease

Chutintorn Sriphrapradang. Endocrine. 2021 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests.

Figures

Fig. 1
Fig. 1
Summary of thyroid function tests
See this image and copyright information in PMC

Comment on

References

    1. O. Vera-Lastra, A. Ordinola Navarro, M.P. Cruz Domiguez, G. Medina, T.I. Sanchez Valadez, L.J. Jara, Two Cases of Graves’ Disease Following SARS-CoV-2 Vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid (2021). 10.1089/thy.2021.0142. - PubMed
    1. G. Zettinig, M. Krebs, Two further cases of Graves’ disease following SARS-Cov-2 vaccination. J. Endocrinol. Invest. (2021). 10.1007/s40618-021-01650-0. - PMC - PubMed
    1. Zhang J, He Q, An C, Mao Q, Gao F, Bian L, Wu X, Wang Q, Liu P, Song L, Huo Y, Liu S, Yan X, Yang J, Cui B, Li C, Wang J, Liang Z, Xu M. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg. Microbes Infect. 2021;10(1):1598–1608. doi: 10.1080/22221751.2021.1957401.. - DOI - PMC - PubMed

Substances